Literature DB >> 7981989

IgM, IgA and IgG class serum antibodies against Klebsiella pneumoniae and Escherichia coli lipopolysaccharides in patients with ankylosing spondylitis.

O Mäki-Ikola1, K Lehtinen, M Nissilä, K Granfors.   

Abstract

Igm, IgA and IgG class serum antibodies against Klebsiella pneumoniae and Escherichia coli lipopolysaccharides (LPS) were studied by ELISA in two separate AS patient populations of 99 and 81 subjects and in 102 healthy blood donors. In the first patient population increased levels of IgM and IgG class antibodies against K. pneumoniae LPS were observed in patients with active AS. In the population with active AS, increased levels of IgM, IgA and IgG class antibodies against K. pneumoniae LPS and IgA class antibodies against E. coli LPS were observed. Sulphasalazine treatment decreased IgM and IgA class antibody levels significantly against K. pneumoniae LPS and IgM class antibodies against E. coli LPS. These findings suggest that a significant part of the anti-Klebsiella antibodies found in AS patients is directed against the LPS component of Klebsiella.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7981989     DOI: 10.1093/rheumatology/33.11.1025

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  4 in total

Review 1.  Clinical, bacteriological, and serological aspects of Klebsiella infections and their spondylarthropathic sequelae.

Authors:  H Sahly; R Podschun
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

Review 2.  Insights into the Role of Infection in the Spondyloarthropathies.

Authors:  Y Liu; M A Penttinen; K Granfors
Journal:  Curr Rheumatol Rep       Date:  2001-10       Impact factor: 4.592

3.  IgA1 and IgA2 subclass antibodies against Klebsiella pneumoniae in the sera of patients with peripheral and axial types of ankylosing spondylitis.

Authors:  O Mäki-Ikola; M Nissilä; K Lehtinen; M Leirisalo-Repo; K Granfors
Journal:  Ann Rheum Dis       Date:  1995-08       Impact factor: 19.103

4.  Ankylosing spondylitis risk factors: a systematic literature review.

Authors:  Mark C Hwang; Lauren Ridley; John D Reveille
Journal:  Clin Rheumatol       Date:  2021-03-22       Impact factor: 3.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.